Indaptus Therapeutics Co-CEO and CSO Salaries Cut to $60K Amidst Financial Restructuring
INDP sits 75% above its 52-week low of $1.65 on light trading volume (0.3× avg).
Summary
Indaptus Therapeutics announced significant salary reductions for its Co-Chief Executive Officer and Chief Science Officer to $60,000 annually, effective January 15, 2026, signaling severe financial constraints and cost-cutting measures.
Key Events · Executive and Board Changes · INDP
-
Executive Salary Reductions
Co-CEO Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, Ph.D. had their annual salaries adjusted to $60,000, effective January 15, 2026, for the remainder of the year.
-
Director Resignation Rescinded
Board member Anthony Maddaluna, who previously intended to resign, has decided to remain on the Board and its Compensation and Nominating Committees.
Analysis · INDP · Life Sciences
The drastic reduction in C-suite executive salaries to $60,000 per annum for a public company, even a micro-cap, is a critical indicator of severe financial distress and aggressive cost-cutting. This move, linked to a prior securities purchase agreement, suggests the company is under significant pressure to conserve capital and extend its operational runway. While the rescission of a director's resignation provides some stability to the board, it is largely overshadowed by the implications of such low executive compensation, which raises serious concerns about the company's long-term viability and immediate financial health. Investors should view this as a strong negative signal regarding the company's financial position.
At the time of this filing, INDP was trading at $2.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $1.65 to $47.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.